P-82 Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer

Abstract

Mutated RAS/BRAF oncoproteins have been identified as key oncogenic drivers across the cancer types including colorectal cancer. Metastatic colorectal cancer (mCRC) patients with mutant RAS/BRAF are ineligible for anti-epidermal growth factor receptor (EGFR) therapy, as RAS/BRAF mutations activate downstream pathways independently of EGFR and induce primary resistance. In particular, KRAS mutations in the amino acid at position 12 in the KRAS protein are common. Nevertheless, previous attempts to therapeutically target mutant forms of KRAS have been unsuccessful, largely due to the lack of suitable drug-binding pockets on the protein.